Allergic Rhinitis (Hay Fever)

Table of Contents

  1. What is Allergic Rhinitis?
  2. Pathophysiology: IgE-Mediated Inflammation
  3. Allergens and Triggers
  4. Diagnosis
  5. Pharmacological Treatment
  6. Allergen Immunotherapy (AIT)
  7. Non-Pharmacological Measures and Allergen Avoidance
  8. Comorbidities: The United Airway
  9. Special Populations
  10. Key Research Papers
  11. Connections
  12. Featured Videos

What is Allergic Rhinitis?

Allergic rhinitis (AR) is an IgE-mediated inflammatory condition of the nasal mucosa triggered by inhaled allergens. When a sensitized person breathes in a substance their immune system has tagged as dangerous — tree pollen, dust mite particles, pet dander, or mold spores — the immune response floods the nasal lining with histamine, leukotrienes, and inflammatory cells, producing the familiar cascade of sneezing, itching, runny nose, and congestion.

It is the most common allergic disease worldwide. Global prevalence ranges from 10 to 30 percent of adults and up to 40 percent of children, with rates rising in westernized countries over the past four decades. In the United States alone, approximately 60 million people are affected each year, making AR more prevalent than diabetes, heart disease, or asthma individually. The annual economic burden in the US exceeds $11 billion, accounting for lost work and school days, outpatient visits, and medication costs — and this figure does not capture the substantial impact on sleep quality, cognitive performance, and quality of life.

AR is classified along two dimensions by the landmark ARIA guidelines (Allergic Rhinitis and its Impact on Asthma, published 2001 and updated 2010):

Clinically, AR is often described by its triggering pattern. Seasonal allergic rhinitis (SAR) — commonly called hay fever — is driven by airborne pollens from trees, grasses, and weeds during their respective seasons. Perennial allergic rhinitis (PAR) persists year-round and is caused by indoor allergens such as house dust mites, pet dander, cockroach particles, and mold. Episodic AR occurs upon sporadic, unpredictable exposure to an allergen that is not routinely encountered — for example, visiting a home with a cat when the patient does not own one. In practice, many patients have both seasonal and perennial components simultaneously.

Despite the colloquial term "hay fever," the condition is not caused by hay and does not produce fever. The label traces to a 19th-century British physician who associated summertime symptoms with hay harvesting — an association that has persisted in popular language long past its accuracy.

Back to Table of Contents

Pathophysiology: IgE-Mediated Inflammation

The development of allergic rhinitis involves two distinct immune phases: an initial sensitization phase and the inflammatory response that follows on re-exposure.

Sensitization Phase

The first time a genetically susceptible person encounters an allergen — say, birch pollen — antigen-presenting cells in the nasal mucosa process the allergen proteins and present them to naive T helper cells. In atopic individuals, the immune response skews toward a Th2 phenotype, driven by cytokines IL-4, IL-13, and thymic stromal lymphopoietin (TSLP) released by airway epithelial cells. Th2 cells then produce IL-4 and IL-13, signaling B cells to undergo class switching and produce allergen-specific IgE antibodies. These IgE molecules coat the surface of mast cells (in tissue) and basophils (in blood) by binding to high-affinity Fc-epsilon-RI receptors. At this point, the person is sensitized but may have no symptoms yet.

Early Phase Reaction

On subsequent allergen exposure, airborne allergen molecules cross-link the surface IgE on mast cells. This cross-linking triggers immediate degranulation within seconds to minutes, releasing preformed mediators — primarily histamine, tryptase, and prostaglandin D2 — and newly synthesized leukotrienes (LTC4, LTD4, LTE4). Histamine acting on H1 receptors in the nasal mucosa causes nasal pruritus and sneezing (sensory nerve stimulation), watery rhinorrhea (gland hypersecretion), and vasodilation contributing to congestion. Prostaglandin D2 amplifies mast cell and basophil recruitment. The early phase peaks within 15 to 30 minutes of exposure.

Late Phase Reaction

Four to eight hours after exposure, a second inflammatory wave develops. Cytokines released during the early phase — IL-5, eotaxin, IL-3, and GM-CSF — recruit and activate eosinophils and T cells into the nasal mucosa. Eosinophil-derived mediators (major basic protein, eosinophil peroxidase) cause direct tissue damage and amplify mucosal edema. This late phase accounts for prolonged nasal congestion, impaired sense of smell, fatigue, and the cognitive fog that patients often call "brain fog." Unlike the early phase, the late phase is less responsive to antihistamines and requires anti-inflammatory treatment such as intranasal corticosteroids.

Nasal Hyperresponsiveness and Priming

Repeated allergen exposure during a pollen season lowers the threshold for mast cell degranulation — a phenomenon called the priming effect. A patient may tolerate low pollen counts at the start of the season but react severely to the same counts weeks later. This also explains why non-specific irritants (cold air, smoke, strong odors) can trigger nasal symptoms in AR patients but not in non-allergic individuals: the inflamed mucosa has become hyperresponsive.

Nasal Polyps

In some patients with chronic AR, persistent type 2 inflammation driven by IL-5 and local IgE production leads to the formation of nasal polyps — soft, non-cancerous growths arising from the sinus epithelium. Polyps contain dense eosinophilic infiltrates and tissue remodeling. When large, they block nasal airflow and produce anosmia (complete smell loss). Nasal polyps are more commonly associated with chronic rhinosinusitis but frequently coexist with AR and aspirin-exacerbated respiratory disease (Samter's Triad).

Back to Table of Contents

Allergens and Triggers

Identifying the specific allergen driving a patient's symptoms is essential for targeted avoidance measures, appropriate pharmacotherapy, and allergen immunotherapy selection. Allergens are broadly divided by whether they cause seasonal or perennial exposure.

Seasonal Pollens

Tree pollens (spring): Oak, birch, cedar, elm, and alder are the dominant spring culprits. Birch is the most extensively studied; its major allergen Bet v 1 (a pathogenesis-related PR-10 protein) is recognized by the immune systems of up to 25 percent of pollen-allergic Europeans. Importantly, Bet v 1 cross-reacts with homologous proteins in raw apple, peach, hazelnut, carrot, celery, and cherry, causing oral allergy syndrome (OAS) — transient lip, tongue, and throat tingling when eating these raw foods. OAS is not anaphylaxis; it typically resolves within minutes and cooking the food destroys the heat-labile allergen.

Grass pollens (late spring to summer): Timothy grass (Phleum pratense), ryegrass, Bermuda grass, and orchard grass produce highly immunogenic pollens. The major allergens Phl p 1 and Phl p 5 are recognized by over 90 percent of grass-allergic patients. Grass pollen cross-reacts with tomato, melon, orange, and peach. Grass pollen is the primary driver of SAR in Europe and many parts of the US, where peak levels occur from May through July.

Weed pollens (late summer to fall): Ragweed (Ambrosia species) is the dominant late-season allergen in North America. Its major allergen Amb a 1 is considered the most potent US pollen allergen — approximately 75 percent of Americans with pollen allergy react to ragweed. A single ragweed plant can produce one billion pollen grains per season, and grains are lightweight enough to travel hundreds of miles on wind currents. The ragweed season typically runs from mid-August through the first frost. Mugwort, sage, and lamb's quarter are additional weed allergens relevant in specific geographic regions. Mugwort (Art v 1) cross-reacts with carrot, celery, peach, apple, and kiwi.

Mold spores: Alternaria and Cladosporium peak in late summer and fall, overlapping with ragweed season and complicating diagnosis. Alternaria sensitization is a particularly important risk factor for life-threatening asthma attacks in children and young adults.

Perennial Allergens

House dust mites (HDM): Dermatophagoides pteronyssinus and D. farinae are microscopic arachnids that feed on shed human skin cells. They thrive in warm (above 68°F / 20°C), humid (above 50% relative humidity) environments and concentrate in mattresses, pillows, upholstered furniture, and carpets. Their major allergens Der p 1 and Der p 2 (proteases and lipid-transfer proteins) are potent sensitizers and among the most common cause of perennial AR globally. Avoidance measures — allergen-impermeable mattress and pillow covers, weekly hot washing of bedding (above 60°C), reducing indoor humidity, removing carpets — can meaningfully reduce allergen load.

Pet dander: Cat (Felis domesticus) allergen Fel d 1, produced in salivary and sebaceous glands, is the most potent pet allergen. It is extremely lightweight (3 micrometers), remains airborne for hours, and adheres to clothing and furnishings. Fel d 1 persists in a home for months to years after a cat is removed. Approximately 15 percent of the general population is sensitized to cat allergen; in asthma patients, the prevalence is 30 to 40 percent. Dog allergen Can f 1 is also common. Keeping pets outdoors, restricting them from the bedroom, running HEPA air purifiers, and washing the animal weekly (limited supporting evidence) can reduce but not eliminate exposure.

Cockroach: Periplaneta americana (American cockroach) and Blattella germanica (German cockroach) produce allergens Bla g 1 and Bla g 2 in their feces, saliva, and shed body parts. Cockroach sensitization is a major driver of AR and severe asthma in inner-city children in the US, where prevalence in low-income urban housing can exceed 50 percent of asthmatic children. Integrated pest management (sealing cracks, eliminating food sources, professional extermination) is the primary avoidance strategy.

Indoor mold: Alternaria and Aspergillus can grow indoors in areas of water damage or high humidity. Stachybotrys chartarum (black mold) rarely produces airborne allergen in quantities sufficient to cause AR but is often blamed in media coverage. Addressing moisture sources, improving ventilation, and professional remediation of water-damaged materials are the key interventions.

Back to Table of Contents

Diagnosis

Allergic rhinitis is primarily a clinical diagnosis supported by allergy testing to identify the specific sensitizing allergen(s). The diagnostic process combines a careful history, physical examination, and objective testing.

Clinical History

Key questions include: When do symptoms occur and do they follow a seasonal pattern? Which symptoms are most prominent — itching, sneezing, rhinorrhea, or congestion? Is there itchy/watery eyes (suggesting allergic rhinoconjunctivitis)? Does exposure to specific environments (grass-cutting, cat visits, damp buildings) trigger symptoms? Is there a personal or family history of asthma, eczema, or food allergy (the "atopic triad")? How severely do symptoms affect sleep, work, and daily activities?

Physical Examination

Nasal examination with a speculum or otoscope reveals characteristic findings: pale, bluish, swollen nasal turbinates (contrasted with the red turbinates of infectious rhinitis), watery clear discharge, and in children, enlarged adenoids. External signs of chronic AR include "allergic shiners" (bilateral infraorbital darkening from venous congestion), the "allergic salute" (an upward nose-rubbing gesture) and its resulting transverse nasal crease, and "geographic tongue"-like mucosal changes in the posterior pharynx from postnasal drip. Cobblestoning of the posterior pharynx (lymphoid hyperplasia) suggests chronic postnasal drainage.

Skin Prick Testing (SPT)

SPT remains the gold standard for identifying specific IgE sensitization. A small drop of standardized allergen extract is placed on the forearm or back, and a lancet pricks the skin through the drop. Results are read at 15 minutes: a wheal (raised area) of 3 mm or greater above the negative saline control, with surrounding flare (redness), constitutes a positive test. SPT is rapid (results in 20 minutes), highly reproducible, inexpensive, and can test dozens of allergens simultaneously. Limitations: first-generation antihistamines must be stopped for 3 to 5 days (second-generation for at least 3 days) before testing; beta-blockers can blunt responses; patients with severe eczema or dermatographism may not be testable.

Specific IgE Blood Testing

ImmunoCAP (Thermo Fisher) and similar platforms quantify allergen-specific IgE in serum in kU/L. Results are graded Class 0 (undetectable) through Class 6 (very high). Blood testing is preferred when SPT is not feasible (active widespread eczema, severe dermatographism, patient cannot stop antihistamines, very high anaphylaxis risk). Component-resolved diagnostics (CRD) take specific IgE testing further by measuring IgE to individual allergen proteins (e.g., Bet v 1, Bet v 2, Phl p 1, Phl p 5, Amb a 1, Der p 1, Der p 2, Fel d 1). CRD helps distinguish primary sensitization (clinically relevant) from cross-reactive sensitization, predicts which patients will develop OAS, and guides AIT formulation in polysensitized patients.

Local Allergic Rhinitis (LAR)

A clinically important but underrecognized entity: approximately 25 percent of patients previously labeled "non-allergic rhinitis" actually have local IgE production confined to the nasal mucosa without detectable systemic IgE (negative SPT and serum IgE). LAR presents identically to systemic AR and responds to the same treatments including AIT. It is diagnosed definitively by nasal allergen provocation testing (NPT) with standardized allergen extract followed by nasal lavage for local IgE measurement — available at specialist centers. LAR matters because these patients benefit from AIT but would be denied it if only serum testing were performed.

Nasal Cytology

Examination of nasal smears (rhinocytogram) reveals elevated eosinophils in allergic rhinitis, helping differentiate it from infectious (neutrophil-predominant) or vasomotor rhinitis (normal cytology). This simple, inexpensive test is underused but valuable when allergy testing results are equivocal.

Back to Table of Contents

Pharmacological Treatment

Treatment is selected based on ARIA symptom severity, the pattern (intermittent vs. persistent), the predominant symptom (congestion vs. sneezing/rhinorrhea), and patient preferences. The 2017 JACI practice parameters from the Joint Task Force on Practice Parameters (JTFPP) remain the primary US clinical guideline.

Intranasal Corticosteroids (INCS) — First-Line Therapy

INCS are the single most effective pharmacological treatment for AR when used regularly. They reduce all four cardinal symptoms — sneezing, pruritus, rhinorrhea, and congestion — by suppressing the entire inflammatory cascade at the mucosal level. Approved agents include fluticasone propionate (Flonase), mometasone furoate (Nasonex), budesonide (Rhinocort), fluticasone furoate (Veramyst/Avamys), triamcinolone acetonide (Nasacort), and ciclesonide (Omnaris). All are similarly effective at recommended doses. Key practical points:

Antihistamines

Oral second-generation H1 antihistamines are preferred over first-generation agents (diphenhydramine, chlorpheniramine) because they are non-sedating (or minimally sedating) at standard doses and do not cause the significant anticholinergic effects (dry mouth, urinary retention, constipation, confusion) of older antihistamines. Approved agents include cetirizine (Zyrtec), levocetirizine (Xyzal), loratadine (Claritin), desloratadine (Clarinex), and fexofenadine (Allegra). They are highly effective for sneezing, pruritus, and rhinorrhea but only modestly effective for nasal congestion (which is less histamine-dependent). They are available OTC and work within 1 to 3 hours of ingestion.

Intranasal antihistamines — azelastine (Astelin, Astepro) and olopatadine (Patanase) — deliver antihistamine directly to the nasal mucosa, achieving faster onset (within 15 to 30 minutes) than oral formulations and with greater local potency. They have a mild bitter taste and can cause mild drowsiness. Useful for breakthrough symptoms and as adjunct to INCS.

Leukotriene Receptor Antagonists

Montelukast (Singulair) blocks the CysLT1 receptor, reducing leukotriene-mediated bronchoconstriction and nasal inflammation. It is modestly effective for AR but significantly less so than INCS. In 2020, the FDA added a Boxed Warning to montelukast for neuropsychiatric adverse events including agitation, depression, suicidal ideation, and completed suicide — particularly in children. Current guidelines recommend montelukast only when INCS and antihistamines are insufficient, or when AR coexists with mild asthma that also benefits from leukotriene blockade. It is no longer a first-line agent for AR alone.

Decongestants

Oral pseudoephedrine (Sudafed) is an alpha-adrenergic agonist that constricts nasal vasculature and effectively reduces congestion. It is useful short-term but carries cardiovascular risks (elevated blood pressure, tachycardia, insomnia) and is contraindicated in uncontrolled hypertension. It is available behind the pharmacy counter (federal law) due to use in methamphetamine synthesis. Topical oxymetazoline (Afrin) provides rapid, potent decongestion within minutes but must not be used for more than 3 consecutive days — prolonged use causes rhinitis medicamentosa (rebound congestion), in which withdrawal of the spray produces severe nasal blockage, often worse than the original condition. Phenylephrine (available OTC) has limited efficacy at approved doses after FDA analysis in 2023.

Combination Therapy

For moderate-to-severe SAR, combining INCS with intranasal antihistamine is more effective than either agent alone. The fixed-dose combination of azelastine/fluticasone propionate (Dymista) is FDA-approved for this indication and demonstrated superiority to monotherapy in the pivotal MEDA-347 trials. INCS plus oral second-generation antihistamine is also a common and effective combination for patients with both congestion and itch/sneeze dominant symptoms.

Biologic Therapy

Omalizumab (Xolair), a monoclonal anti-IgE antibody, is FDA-approved for moderate-to-severe persistent asthma and chronic idiopathic urticaria, and has demonstrated benefit in AR in clinical trials — particularly in patients with high total IgE and comorbid moderate-to-severe persistent asthma. It is not FDA-approved specifically for isolated AR and is reserved for severe cases with comorbid asthma. Newer biologics targeting IL-4/IL-13 (dupilumab) and IL-5 (mepolizumab) are showing promise in nasal polyp disease overlapping with AR.

Back to Table of Contents

Allergen Immunotherapy (AIT)

Allergen immunotherapy is the only disease-modifying treatment for allergic rhinitis. While medications suppress symptoms during treatment, AIT reprograms the immune system to tolerate the offending allergen — producing benefits that persist for years after the course is completed. AIT reduces symptom severity, decreases medication requirements, prevents the development of new allergen sensitizations, and — most importantly — reduces the risk that AR will progress to asthma. A landmark meta-analysis found that AIT reduced the rate of asthma development by approximately 50 percent in children with AR.

Subcutaneous Immunotherapy (SCIT)

Traditional "allergy shots" involve injecting escalating concentrations of allergen extract under the skin, typically in the upper arm. The standard protocol involves:

SCIT is effective for most inhalant allergens — pollens, dust mites, molds, animal danders, cockroach — and achieves clinically meaningful symptom reduction in approximately 85 percent of patients. The primary limitation is the risk of systemic allergic reactions, including anaphylaxis (approximately 1 in 1 million injection visits). Patients must remain under observation in the clinic for 20 to 30 minutes after each injection. SCIT is contraindicated in severe uncontrolled asthma (FEV1 < 70% predicted) and is used with caution in patients on beta-blockers (which can blunt epinephrine response to anaphylaxis). SCIT is generally covered by health insurance in the US.

Sublingual Immunotherapy (SLIT)

SLIT delivers allergen extract under the tongue, where the abundant tolerogenic dendritic cells and regulatory T cells of oral mucosa facilitate immune tolerance without the systemic risk of injections. Two delivery forms exist: drops (SLIT-drops, widely used in Europe but not FDA-approved in the US) and tablets (SLIT-tablets, FDA-approved in the US for specific allergens):

SLIT tablets are taken daily at home (after an initial observed first dose in the clinic), without office visits. Anaphylaxis risk is substantially lower than SCIT. Local reactions (oral pruritus, tongue tingling, lip swelling) are common initially and usually mild. SLIT should be started 3 to 4 months before the relevant pollen season and continued for 3 to 5 years for sustained benefit. Insurance coverage for SLIT tablets varies; they may require prior authorization and are more expensive out-of-pocket than SCIT for many patients.

Mechanisms of Tolerance Induction

AIT shifts the immune response from Th2 toward a tolerogenic profile by: increasing allergen-specific IgG4 (blocking antibodies that compete with IgE for allergen binding), inducing regulatory T cells (Tregs, particularly IL-10 and TGF-beta producing Tr1 cells), reducing mast cell and basophil reactivity, and eventually suppressing local IgE production. These mechanisms explain why benefits persist long after the course ends, and why AIT-treated patients can tolerate previously symptomatic allergen exposures.

Back to Table of Contents

Non-Pharmacological Measures and Allergen Avoidance

Allergen avoidance is the logical first step in AR management — reducing the allergen burden reduces the immune response required to handle it. While complete avoidance is rarely achievable, significant reductions in exposure can meaningfully improve symptom control and reduce medication requirements.

Nasal Saline Irrigation

High-volume nasal saline irrigation (e.g., NeilMed Sinus Rinse, Neti pot with isotonic or hypertonic saline) mechanically clears pollen, allergen particles, and inflammatory mediators from the nasal mucosa, reduces mucosal edema, and enhances mucociliary clearance — the nasal lining's own self-cleaning mechanism. It has an excellent safety profile (only risk is contamination with unsterile water, notably Naegleria fowleri — use only distilled, sterile, or previously boiled water). Daily irrigation during peak allergen season, ideally after outdoor exposure, is supported by multiple randomized trials and recommended as an adjunct to pharmacotherapy in national guidelines.

Dust Mite Control Measures

Patients sensitized to house dust mites should: encase mattresses, box springs, and pillows in allergen-impermeable covers (dense weave, <10 micron pore size); wash all bedding in water at or above 60°C (140°F) weekly to kill mites and remove allergen; maintain indoor relative humidity below 50% using air conditioners or dehumidifiers (mites cannot survive below 40% RH); consider removing wall-to-wall carpets, particularly in bedrooms (hardwood or tile accumulates far less allergen); and use HEPA-filtered vacuum cleaners. These measures, in combination, are more effective than any single intervention and have been shown to reduce allergen concentrations and improve AR control.

Pet Allergen Strategies

The most effective measure is rehoming the pet — an option few patients pursue. Realistic alternatives include keeping the pet out of the bedroom (the room where exposure time is longest), running HEPA air purifiers, washing the pet weekly (weak but cumulative evidence), and using allergen-impermeable mattress covers. Cat allergen (Fel d 1) is particularly persistent: even after a cat is removed from a home, detectable allergen levels can persist for 20 to 24 weeks without aggressive cleaning. Some patients sensitized to cat allergen tolerate low-allergen cat breeds (e.g., Siberian, Balinese) with lower Fel d 1 production — individual responses vary considerably.

Pollen Avoidance

Pollen counts peak on warm, dry, windy mornings (typically 5 to 10 AM) and drop on cool, wet, or still days. Practical avoidance measures include: checking daily pollen counts (AAAAI National Allergy Bureau, AccuWeather, local weather apps) and staying indoors when counts are high; keeping car and home windows closed during peak season; showering and changing clothes after outdoor activities to remove pollen; wearing wraparound sunglasses outdoors (reduces eye exposure); and using nasal saline rinse immediately after coming indoors. Nasal filters (Rhinix, First Defense nasal guard) — small, barely visible inserts placed at the nasal opening — can reduce inhaled pollen by 70 to 80 percent and are a useful option for outdoor workers or those who cannot avoid high-pollen environments. Starting INCS therapy 1 to 2 weeks before the anticipated local pollen season and taking it preemptively (before first symptoms) is more effective than reactive dosing.

Indoor Air Quality

HEPA air purifiers (capable of capturing particles down to 0.3 microns, including most allergen particles) can reduce airborne cat, dust mite, and mold allergen in enclosed spaces. They are most effective in rooms with high occupancy time, particularly bedrooms. Change filters per manufacturer recommendation. Whole-house HVAC filters with MERV 13 ratings or higher can also reduce airborne allergen. Avoid tobacco smoke exposure, which amplifies nasal inflammation and sensitization.

Back to Table of Contents

Comorbidities: The United Airway

Allergic rhinitis rarely exists in isolation. The "united airway" concept — supported by extensive epidemiological, mechanistic, and clinical evidence — holds that the nose and bronchi are one functionally continuous system, sharing epithelium, immune regulation, and inflammatory mediators. What happens in the nose reverberates throughout the airway. Understanding and treating these comorbidities is essential to managing the AR patient comprehensively.

Asthma

AR and asthma coexist in 80 percent of asthmatic patients; conversely, 20 to 40 percent of AR patients have asthma. Untreated or poorly controlled AR worsens asthma control through multiple mechanisms: mouth breathing bypasses the nasal air-filtering and humidifying functions; nasal inflammatory mediators drain into the bronchi via postnasal drip; nasally-initiated neural reflexes (the nasobronchial reflex) increase bronchial hyperresponsiveness; and systemic cytokine spillover (IL-5, IL-13) promotes airway eosinophilia. Effective treatment of AR with INCS has been shown in multiple trials to reduce asthma exacerbation rates and emergency department visits for asthma.

Chronic Rhinosinusitis (CRS)

Inflammation of the sinus mucosa — chronic rhinosinusitis — is a direct extension of AR-related nasal mucosal inflammation into the paranasal sinuses. The ARIA task force estimates that rhinitis is present in 60 to 80 percent of sinusitis patients. CRS with nasal polyps overlaps heavily with AR, particularly in type-2-high patients. The distinction matters clinically: CRS may require additional therapy (extended antibiotic courses for CRS-without-polyps; biologics or endoscopic sinus surgery for CRS-with-polyps).

Otitis Media with Effusion

In children, nasal inflammation extends to the Eustachian tube, impeding drainage from the middle ear and causing fluid accumulation — otitis media with effusion (glue ear). This produces conductive hearing loss that can affect speech and language development and academic performance. Adenoid hypertrophy from chronic postnasal drainage compound this by obstructing the Eustachian tube orifice. Treating AR with INCS can improve Eustachian tube function and reduce glue ear recurrence.

Sleep Disturbance and Daytime Fatigue

Nasal congestion forces mouth breathing during sleep, contributing to snoring, upper airway resistance syndrome, and frank obstructive sleep apnea. Poor sleep quality from AR-related nighttime symptoms produces daytime fatigue, impaired concentration, and mood disturbance that can be misattributed to depression or ADHD — particularly in children. Studies comparing quality-of-life scores in AR patients to those with other chronic conditions find impairment equivalent to or greater than that caused by moderate asthma.

Allergic Conjunctivitis

Between 80 and 95 percent of SAR patients have concurrent allergic rhinoconjunctivitis — itchy, watery, red eyes with conjunctival edema (chemosis) driven by the same IgE-mast cell mechanism in the conjunctival mucosa. Topical ophthalmic antihistamine/mast cell stabilizer combinations (olopatadine [Pataday], ketotifen [Zaditor], epinastine [Elestat]) are the preferred treatment for ocular symptoms; oral antihistamines provide partial relief but topical agents are more effective for eye symptoms specifically. Avoid topical vasoconstrictors (tetrahydrozoline ["Visine"]) for the same reasons as nasal decongestants — rebound redness with overuse.

Smell and Taste

Chronic nasal mucosal edema and, especially, nasal polyps progressively impair olfactory function. Anosmia (complete smell loss) is devastating to quality of life and food enjoyment. INCS and, if needed, short oral corticosteroid courses can transiently restore smell in inflammatory anosmia. Surgical polypectomy followed by INCS maintenance is the most durable treatment for polyp-driven anosmia.

Back to Table of Contents

Special Populations

Pediatric Patients

AR affects approximately 40 percent of children and is frequently misdiagnosed as recurrent viral upper respiratory infections — parents note that their child "always has a cold." Key differences from adult AR include greater adenoid hypertrophy (causing mouth breathing, snoring, sleep-disordered breathing, and "adenoid facies"), higher rates of Eustachian tube dysfunction and otitis media, and pronounced academic and behavioral impacts (AR significantly impairs concentration and school performance, particularly during examination periods coinciding with peak pollen season).

Treatment in children generally follows adult principles with age-appropriate dose adjustments. Second-generation oral antihistamines (cetirizine approved for children ≥2 years; loratadine, fexofenadine for ≥2 or ≥6 years depending on formulation) are first-line for mild symptoms. INCS are safe in children at recommended doses; the minimal systemic exposure at therapeutic doses does not meaningfully affect growth in most studies, but the minimum effective dose should be used and growth monitored during prolonged treatment. AIT in children is particularly valuable: pediatric studies demonstrate that SCIT reduces rates of new allergen sensitization and prevents the progression of AR to asthma — an opportunity to alter the natural history of atopic disease rather than simply suppress it.

Pregnancy

AR affects up to 30 percent of pregnant women and can worsen due to pregnancy-related mucosal edema (estrogen-mediated). Treatment decisions must balance symptom control (uncontrolled AR impairs sleep quality and potentially fetal oxygenation) against medication safety.

Elderly Patients

Allergic rhinitis in older adults is often underdiagnosed because AR prevalence is believed to decline with age (IgE levels and atopy rates do fall after midlife). When present, AR management in the elderly requires attention to medication risks:

Back to Table of Contents

Key Research Papers

  1. Bousquet J, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) — The landmark 2001 WHO initiative that created the first evidence-based classification and treatment guidelines for AR, introducing the intermittent/persistent and mild/moderate-severe framework that replaced the seasonal/perennial binary.
    J Allergy Clin Immunol. 2001;108(5 Suppl):S147–S334. PMID 11536452
  2. Dykewicz MS, et al. Rhinitis 2020: A Practice Parameter Update of the Joint Task Force on Practice Parameters (JTFPP) — Comprehensive US clinical practice guideline covering diagnosis, pharmacotherapy, immunotherapy, and comorbidity management.
    J Allergy Clin Immunol. 2017;140(2):348–359. PMID 28602936
  3. Dhami S, et al. Allergen immunotherapy for allergic rhinitis: A systematic review and meta-analysis — EAACI 2017 meta-analysis demonstrating AIT efficacy across both SCIT and SLIT modalities, informing European practice guidelines.
    Allergy. 2017;72(11):1597–1631. PMID 28044320
  4. Passalacqua G, et al. Sublingual immunotherapy: what have we learnt from the most recent studies? — Review of the mechanism, efficacy, and safety of SLIT including the newly FDA-approved tablet formulations, with comparison to SCIT.
    Clin Exp Allergy. 2013;43(9):1010–1014. PMID 23808354
  5. Wahn U, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis — Pivotal RCT demonstrating SLIT-tablet (Oralair) efficacy in children, showing reduction in symptom-medication scores vs. placebo.
    J Allergy Clin Immunol. 2009;123(1):160–166. PMID 19376582
  6. Canonica GW, et al. A survey of the burden of allergic rhinitis in Europe: The "Allergies in Europe" (AIRWAY) study — Real-world evidence for the pervasive undertreatment of AR and its impact on asthma control across European populations.
    Allergy. 2016;71(7):1049–1059. PMID 26686536
  7. Colas C, et al. Sensitization to Alternaria and Cladosporium by nasal patency and asthma in patients with allergic rhinitis — Demonstrates the disproportionate severity of mold sensitization in driving asthma risk relative to pollen sensitization.
    Ann Allergy Asthma Immunol. 2006;96(6):824–830. PMID 16455450
  8. Cox L, et al. Sublingual immunotherapy: A comprehensive review — Systematic review examining the evidence base for SLIT, mechanisms of tolerance, and practical guidance on patient selection and administration.
    J Allergy Clin Immunol. 2011;127(1):12–27. PMID 21982320
  9. Simons FER, et al. World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxis — While focused on anaphylaxis, this guideline covers H1 antihistamine pharmacology across age groups including pregnancy and the elderly, with specific dosing recommendations.
    World Allergy Organ J. 2014;7(1):9. PMID 24506954
  10. Meltzer EO, et al. MP29-02 (azelastine hydrochloride/fluticasone propionate) nasal spray is superior to monotherapy with fluticasone propionate for the treatment of seasonal allergic rhinitis — Pivotal trial for the Dymista combination product demonstrating superiority of combined intranasal antihistamine plus corticosteroid over steroid monotherapy.
    J Allergy Clin Immunol. 2012;129(5):1282–1289. PMID 22626539
  11. Zhang Y, et al. Allergic rhinitis in China — Systematic review documenting the rising epidemiology of AR in China (prevalence increasing from ~11% in 2005 to ~18% in 2011 in self-report surveys), with geographic and urban-rural patterns relevant to understanding global AR trends.
    Allergy Asthma Immunol Res. 2018;10(6):595–606. PMID 29194853
  12. Roberts G, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis — Comprehensive European evidence-based guideline on AIT for AR, including patient selection criteria, monitoring protocols, and long-term outcomes.
    Allergy. 2018;73(4):765–798. PMID 29124772

Back to Table of Contents

Connections

Back to Table of Contents